KX2-391

DRUG3 trials

Sponsors

Athenex, Inc., Kinex Pharmaceuticals Inc.

Conditions

Acute Myelogenous LeukemiaBone-Metastatic, Castration-Resistant Prostate CancerLymphomaSolid Tumors

Phase 1

Evaluation of KX2-391 in Patients With Advanced Malignancies

CompletedNCT00658970

Athenex, Inc.Lymphoma, Solid Tumors

Start: 2007-11-30End: 2011-05-31Target: 50Updated: 2011-06-08

Evaluation of KX2-391 in Elderly Subjects With Acute Myeloid Leukemia (AML)

CompletedNCT01397799

Kinex Pharmaceuticals Inc.Acute Myelogenous Leukemia

Start: 2013-12-31End: 2014-07-31Updated: 2015-12-07

Phase 2

Safety and Efficacy Study of KX2-391 for Treatment of Bone-Metastatic, Castration-Resistant Prostate Cancer

CompletedNCT01074138

Athenex, Inc.Bone-Metastatic, Castration-Resistant Prostate Cancer

Start: 2010-02-28End: 2012-10-31Updated: 2023-02-02

Related Papers

A phase Ib dose escalation study of oral monotherapy with KX2-391 in elderly patients with acute myeloid leukemia.

2022-05-175 citations

A phase 1b dose escalation study to evaluate safety, tolerability and pharmacokinetics of oral monotherapy with KX2-391 in elderly subjects with acute myeloid leukemia who are refractory to or have declined standard induction therapy.

Journal of Clinical Oncology2017-05-2010 citations